Simplify Asset Management Inc. reported 95 positions worth $443.72M for the quarter ended Sep 30, 2026, down 8.0% on the prior quarter. It opened 11 new positions, added to 7, trimmed 64 and exited 35. Its largest holding is ELI LILLY & Co at 7.8% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| HUM Humana Inc | +65.2K | – | $24.87M | 5.61% |
| ARQT Arcutis Biotherapeutics, Inc. | +865.9K | – | $22.88M | 5.16% |
| LLY ELI LILLY & Co | +15.4K | +104.5% | $17.79M | 7.85% |
| AVTR Avantor, Inc. | +965.9K | – | $14.54M | 3.28% |
| SMMT Summit Therapeutics Inc. | +510.1K | – | $8.63M | 1.94% |
| GRAL GRAIL, Inc. | +43.0K | – | $6.02M | 1.36% |
| GH Guardant Health, Inc. | +21.4K | +77.5% | $3.81M | 1.97% |
| HSIC Henry Schein Inc | +38.0K | – | $3.19M | 0.719% |
| COLL Collegium Pharmaceutical, Inc | +93.5K | – | $2.04M | 0.46% |
| PCT PureCycle Technologies, Inc. | +278.1K | +9.1% | $1.23M | 3.31% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| NVO Novo Nordisk A S | -504.9K | -100.0% | $24.21M | Exited |
| TXG 10x Genomics, Inc. | -224.7K | -76.7% | $20.30M | 1.39% |
| UTHR UNITED THERAPEUTICS Corp | -29.3K | -64.6% | $15.89M | 1.96% |
| ALGN Align Technology Inc | -66.8K | -100.0% | $11.27M | Exited |
| DHR Danaher Corp | -33.3K | -77.8% | $7.38M | 0.475% |
| ELV Elevance Health, Inc. | -18.3K | -71.4% | $7.10M | 0.641% |
| BHVN Biohaven Ltd. | -489.6K | -47.1% | $6.54M | 1.66% |
| AZN Astrazeneca Plc | -34.2K | -100.0% | $6.48M | Exited |
| IBIT iShares Bitcoin Trust ETF | -129.6K | -26.6% | $6.14M | 3.81% |
| EYPT EyePoint, Inc. | -400.0K | -100.0% | $5.72M | Exited |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| HUM Humana Inc | +65.2K | $24.87M | 5.61% |
| ARQT Arcutis Biotherapeutics, Inc. | +865.9K | $22.88M | 5.16% |
| AVTR Avantor, Inc. | +965.9K | $14.54M | 3.28% |
| SMMT Summit Therapeutics Inc. | +510.1K | $8.63M | 1.94% |
| GRAL GRAIL, Inc. | +43.0K | $6.02M | 1.36% |
| HSIC Henry Schein Inc | +38.0K | $3.19M | 0.719% |
| COLL Collegium Pharmaceutical, Inc | +93.5K | $2.04M | 0.46% |
| CABA Cabaletta Bio, Inc. | +556.2K | $1.07M | 0.241% |
| PROK Prokidney Corp. | +483.7K | $803.01K | 0.181% |
| CRWD CrowdStrike Holdings, Inc. | +1,535 | $406.39K | 0.092% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| NVO Novo Nordisk A S | -504.9K | $24.21M | 5.02% |
| ALGN Align Technology Inc | -66.8K | $11.27M | 2.34% |
| AZN Astrazeneca Plc | -34.2K | $6.48M | 1.34% |
| EYPT EyePoint, Inc. | -400.0K | $5.72M | 1.19% |
| ISRG Intuitive Surgical Inc | -7,492 | $2.98M | 0.617% |
| OWL Blue Owl Capital Inc. | -106.5K | $931.88K | 0.193% |
| MRK Merck & Co., Inc. | -7,167 | $920.96K | 0.191% |
| CIM Chimera Investment Corp | -51.0K | $680.67K | 0.141% |
| BSX Boston Scientific Corp | -15.0K | $640.80K | 0.133% |
| CAT Caterpillar Inc | -558 | $594.21K | 0.123% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | LLY ELI LILLY & Co | Healthcare | 30.1K | $34.81M | 7.85% | +15.4K | +104.5% | Added | 0% |
| 2 | PAGP Plains Gp Holdings Lp | Energy | 1.27M | $32.95M | 7.43% | 0 | 0.0% | Unchanged | 0.64% |
| 3 | HUM Humana Inc | Healthcare | 65.2K | $24.87M | 5.61% | +65.2K | – | New | 0.05% |
| 4 | ARQT Arcutis Biotherapeutics, Inc. | Healthcare | 865.9K | $22.88M | 5.16% | +865.9K | – | New | 0.66% |
| 5 | WRBY Warby Parker Inc. | Consumer Discretionary | 627.3K | $17.43M | 3.93% | +40.3K | +6.9% | Added | 0.58% |
| 6 | IBIT iShares Bitcoin Trust ETF | Others | 357.3K | $16.91M | 3.81% | -129.6K | -26.6% | Reduced | 0.03% |
| 7 | ABBV AbbVie Inc. | Healthcare | 64.3K | $16.81M | 3.79% | -199 | -0.3% | Reduced | 0% |
| 8 | JNJ Johnson & Johnson | Healthcare | 62.5K | $16.53M | 3.73% | -10.4K | -14.3% | Reduced | 0% |
| 9 | TMO Thermo Fisher Scientific Inc. | Healthcare | 24.1K | $16.29M | 3.67% | +1,051 | +4.6% | Added | 0.01% |
| 10 | UNH Unitedhealth Group Inc | Healthcare | 41.4K | $15.20M | 3.43% | -809 | -1.9% | Reduced | 0% |
| 11 | PCT PureCycle Technologies, Inc. | Basic Materials | 3.33M | $14.67M | 3.31% | +278.1K | +9.1% | Added | 1.81% |
| 12 | AVTR Avantor, Inc. | Industrials | 965.9K | $14.54M | 3.28% | +965.9K | – | New | 0.14% |
| 13 | JAZZ Jazz Pharmaceuticals plc | Healthcare | 53.8K | $12.45M | 2.81% | -14.8K | -21.5% | Reduced | 0.08% |
| 14 | GILD Gilead Sciences, Inc. | Healthcare | 81.1K | $12.08M | 2.72% | -264 | -0.3% | Reduced | 0.01% |
| 15 | DGX Quest Diagnostics Inc | Healthcare | 49.5K | $11.55M | 2.6% | -177 | -0.4% | Reduced | 0.05% |
Tip. Select a row to see that position’s full history at Simplify Asset Management.
As of its Q3 2026 13F filing, Simplify Asset Management Inc.’s five largest positions were ELI LILLY & Co (LLY) at 7.8%, Plains Gp Holdings Lp (PAGP) at 7.4%, Humana Inc (HUM) at 5.6%, Arcutis Biotherapeutics, Inc. (ARQT) at 5.2%, Warby Parker Inc. (WRBY) at 3.9% of the reported portfolio.
Simplify Asset Management Inc. reported a 13F portfolio worth $443.72M across 95 positions for Q3 2026. That is down 8.0% from the previous quarter.
Its largest purchases by value were Humana Inc ($24.87M), Arcutis Biotherapeutics, Inc. ($22.88M), ELI LILLY & Co ($17.79M). It opened 11 new positions.
Its largest sales by value were Novo Nordisk A S ($24.21M), 10x Genomics, Inc. ($20.30M), UNITED THERAPEUTICS Corp ($15.89M). It exited 35 positions entirely.
From the Form 13F-HR reports Simplify Asset Management Inc. files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.